http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
Massive hepatocellular carcinoma (HCC) is defined as a tumor(s) involving 1 segment or more, with indistinct boundary in ≥50% of margins. There have been only few studies regarding the treatment response in patients with massive HCC. Therefore, in this review, the author focused on the treatment response in HCC of ≥10 cm in size. Reported survival rates after surgical resection are 61~66% at 1 year, 38~44% at 3 years, and 28~31% at 5 years. However, surgical resection is usually performed in patients with solitary tumor and good hepatic reserve function, and without gross vascular invasion. In addition, it was reported that surgical complication rate or mortality increases in tumors of ≥10 cm. Therefore, these data do not represent the outcome after surgical resection in patients with massive HCC. Transarterial chemoembolization (TACE) can induce objective response in about 65% of patients with HCC(s) of ≥10 cm according to modified EASL criteria. However, frequent intra- and extra-hepatic metastases are unavoidable and the survival rate was 43% at 1 year and 20% at 2 years. Of note, 11% of cases suffered from serious adverse effects such as renal impairment, sepsis and/or hepatic failure after TACE. Recently, sorafenib has been shown to increase patient`s survival, but the survival benefit is not still satisfactory. Other systemic chemotherapies using various combinations of cytotoxic agents usually show 10-20% of objective response, but there has been no evidence that it can prolong overall patient`s survival. There also has been no evidence that intra-arterial chemotherapy with or without implantable drug delivery system is superior to conventional chemotherapy or can prolong patient`s survival. In summary, treatment response in large HCC(s) is not still satisfactory and treatment-related adverse effects are considerable. Therefore, treatment should be performed in well-selected patients.
The introduction of lamivudine (LAM) has opened a new era for the treatment of chronic hepatitis B (CHB). However, the major drawback of LAM, which currently limits its use as first-line therapy, is the high rate of occurrence of drug resistance. In patients with LAM-resistant CHB, recent long-term findings have indicated that adding adefovir (ADV) to ongoing LAM therapy was more beneficial than switching to ADV alone, because the former showed a diminished rate of resistance to ADV with a well-tolerated safety profile. Above all, the most important strategy for CHB treatment must be to use a potent first-line antiviral with high genetic barriers to resistance in order to prevent the development of multidrug resistance. (Korean J Med 77:713-715, 2009)
허내윤 ( Nae Yun Heo ),이한주 ( Han Chu Lee ),심주현 ( Ju Hyun Shim ),김강모 ( Kang Mo Kim ),임영석 ( Young Suk Lim ),정영화 ( Young Hwa Chung ),이영상 ( Yung Sang Lee ),서동진 ( Dong Jin Suh ) 대한간암연구학회(구 대한간암연구회) 2011 대한간암학회지 Vol.11 No.1
A surgical resection is a major curative treatment of hepatocellular carcinoma (HCC) in Korea. However, the respectability of HCC at the time of diagnosis is low (10-30%) because the cancer is often identified as advanced stage. Nevertheless, some of the patients were known to have a curative resection after successful downstaging therapy. We report a HCC with bile duct invasion which was successfully downstaged by the transarterial chemoembolization and treated by surgical resection.
유동준 ( Dong Jun Yoo ),이한주 ( Han Chu Lee ),유은실 ( Eunsil Yu ),진영주 ( Young Joo Jin ),심주현 ( Ju Hyun Shim ),김강모 ( Kang Mo Kim ),임영석 ( Young Suk Lim ),정영화 ( Young Hwa Chung ),이영상 ( Yung Sang Lee ),서동진 ( Dong 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.1
EPP는 ferrochelatase의 결핍이나 활성 감소로 프로토포르피린이 적혈구, 간, 혈장 등에 축적되는 유전질환이다 축적된 프로토포르피린은 EPP의 주된 임상적 특징인 광과민 증상과 간질환을 일으키게 된다. EPP로 인한 간질환에 대해 다양한 치료법이 개발되고 있으나, 효과적인 치료 방법은 아직 없다. 그 중 cholestyramine resion의 유용성에 대한 보고는 드물며, 다른 치료와 같이 대부분 사용되었다. 저자들은 cholestyramine resion의 단독치료로 성공적인 결과를 나타낸 사례를 보고하는 바이다. 향후 EPP로 인한 간질환의 증상 및 예후 개선을 위해서, 이번 사례를 포함한 더 많은 연구가 필요하다. Erythropoietic protoporphyria (EPP) is a rare disorder of heme biosynthesis caused by mutations in the gene encoding the enzyme ferrochelatase. In EPP, deficient ferrochelatase activity leads to the excessive production and biliary excretion of protoporphyrin (PP). The major clinical features of EPP are photosensitivity and hepatobiliary disease that may progress to severe liver disease, that are caused by the toxicity of PP. EPP-related liver disease has been treated medically or surgically including liver transplantation. We described a 20-year-old male with severe liver disease who was diagnosed with EPP based on clinical and laboratory findings. He was treated with cholestyramine resin. Six months after the treatment, he was doing well without any abdominal pain or photosensitivity. (Korean J Hepatol 2010;16:83-88)